TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04623528

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 and T2 relaxometry of the liver parenchyma
Description: Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 and T2 relaxometry of the liver parenchyma
Description: Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
Study: NCT02697799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-level recruitment strategy consent form
Description: Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
Study: NCT04623528

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 and T2 relaxometry of the liver parenchyma
Description: Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 and T2 relaxometry of the liver parenchyma
Description: Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 and T2 relaxometry of the liver parenchyma
Description: Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
Study: NCT02697799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mid-level recruitment strategy consent form
Description: Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
Study: NCT04449887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiangsha Liujunzi granules
Description: A traditional Chinese medicine compound, taken three times a day, one bag at a time, for a total of 28 days
Study: NCT04623528

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 and T2 relaxometry of the liver parenchyma
Description: Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
Study: NCT01875835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multilink-Vision stent(Abbott Vascular, Santa Clara, California, USA)
Study: NCT04156477

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Intake of weight adjusted drink of a ketone ester

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Isocaloric and - volumetric taste adjusted drink
Study: NCT03722108

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regorafenib and Irinotecan
Description: Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
Study: NCT04156477

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Description: Isovolumetric taste adjusted tap water (placebo)
Study: NCT03998878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Participants will be instructed to follow a low-carbohydrate diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction
Description: Participants will be instructed to follow intermittent energy restriction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hunger Training
Description: Participants will be instructed to follow Hunger Training.
Study: NCT01545258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physiotherapy supervised exercise training. 60 minutes 3 times per week
Study: NCT04951440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrate ketone oxazine
Description: Intervention group: 30min intravenous point. Drop qiu was given 1400 mg of injected sichuan nitrone I bed, and the drug was given 100 mL at day F Set 12 h, and at odds with another 7 days, that is, about 14 times in total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate ketone oxazine
Description: Intervention group: 30min intravenous point. Drop qiu was given 1400 mg of injected sichuan nitrone I bed, and the drug was given 100 mL at day F Set 12 h, and at odds with another 7 days, that is, about 14 times in total.
Study: NCT02367131

Intervention type: DRUG
Intervention: JARDIANCE®
Description: JARDIANCE®
Study: NCT03708848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT03722108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
Study: NCT00587249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria ICC-1132
Description: ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria ICC-1132
Description: ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
Study: NCT03374072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Siblings FORWARD program
Description: Siblings will participate in a program developed by the researchers designed to engage adults with their autistic sibling and other family members to plan for the future. The Siblings FORWARD program will be implemented by community service providers already working with autistic adults. The program will involve a series individual and joint sessions with siblings and autistic adults using Zoom.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only Condition
Description: Siblings will be provided with online information about services for adults with ASD and future planning.
Study: NCT00611637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV pp65 Specific T Cells
Description: Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
Study: NCT03708848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: antibiotic for H. pylori eradication
Study: NCT01677546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSII+BC+CL
Description: Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSII+BC
Description: Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
Study: NCT03852004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ostheopathy
Description: standardized osteopathic treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: simulated osteopathic treatment
Description: standardized simulated osteopathic treatment
Study: NCT04343300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Intervention of12 weeks of Pilates

Intervention type: OTHER
Group type: OTHER
Intervention: exercise without Pilates
Description: exercise without Pilates
Study: NCT00587249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria ICC-1132
Description: ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel
Description: Aluminum hydroxide gel.
Study: NCT00736957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)
Description: Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
Study: NCT02372370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedle pretreatment + MAL-PDT
Description: Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
Study: NCT03395587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, tumor lysate-loaded, mature dendritic cells (DC)
Description: Advanced therapy medicinal product (ATMP) produced at the University Hospital Düsseldorf according to Good Manufacturing Practice (GMP) with production permission according §13 AMG (German Drug Law) of the local authorities (Bezirks¬regierung Düsseldorf)
Study: NCT00587249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel
Description: Aluminum hydroxide gel.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel
Description: Aluminum hydroxide gel.
Study: NCT02088333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mCRC intervention
Description: a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
Study: NCT02372370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sandpaper pretreatment + MAL-PDT
Description: Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
Study: NCT02088333

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Lifestyles video
Description: a brief video about healthy lifestyle habits displayed on a tablet device
Study: NCT01618487

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic tenotomy
Description: This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open tenotomy
Description: This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement and repair
Description: This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
Study: NCT02710240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Study: NCT02372370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage pretreatment + MAL-PDT
Description: Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT
Description: Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
Study: NCT03395587

Intervention type: DRUG
Group type: OTHER
Intervention: standard therapy
Description: temozolomide, fractionated radiochemotherapy
Study: NCT02372370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT
Description: Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL Control.
Description: Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Untreated Control
Description: Untreated control. No interventions.
Study: NCT02680509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sympathicotomy R3
Description: sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
Study: NCT00234273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme in Adapted Physical Activity (APA)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education primarily focused on dietary

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic education primarily focused on dietary
Study: NCT00886184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermia.
Description: Induction of pre hospital therapeutic hypothermia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No early hypothermia
Description: Induction of therapeutic hypothermia only once arrived at hospital.
Study: NCT04210778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive orientation to daily occupational performance (CO-OP)
Description: The CO-OP is a client-centered, goal directed approach aimed at enabling individuals to identify strategies that will improve daily function. A Weekly (1hr) session is delivered remotely via video conferencing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (BrainHQ, posit science)
Description: The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training (BrainHQ, posit science)
Description: The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)
Study: NCT04204122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigamox
Description: -FDA approved medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: -The placebo is artificial tear drops
Study: NCT03470961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Tlymphocyte Globulins
Description: Induction therapy regimen in simultaneous pancreas kidney transplantation
Study: NCT01161017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised
Study: NCT03679702

Intervention type: DEVICE
Group type: OTHER
Intervention: Viveve System
Description: Radiofrequency device utilized in general surgical procedures for electrocoagulation and hemostasis.
Study: NCT05226481

Intervention type: OTHER
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Description: Trauma-focused cognitive-behavioral therapy (TF-CBT) is an evidence-based method for the treatment of posttraumatic stress among youth.
Study: NCT04529057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment
Description: The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment
Description: The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment
Description: The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
Study: NCT01913756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gamalost (Norwegian traditional cheese)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gouda-type cheese
Study: NCT02710240

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative near-infrared (NIR)
Study: NCT00920374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™/Influsplit SSW®
Description: single intramuscular dose on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™/Influsplit SSW®
Description: single intramuscular dose on Day 0
Study: NCT01414036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Traditional Care control
Description: Educational brochure, list of hospital and community resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
Study: NCT03939520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone and nintedanib
Description: The experimental group will receive pirfenidone 2403 mg per day (at least 1602 mg) in combination with nintedanib 300 mg per day (at least 200 mg) during 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pirfenidone or nintedanib
Description: The second intervention group will switch from one monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).

Intervention type: DRUG
Group type: OTHER
Intervention: pirfenidone or nintedanib
Description: The control group will keep on the same monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
Study: NCT01031693

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: daily sessions for 5 days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: daily sessions for 5 days
Study: NCT02953275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vedolizumab
Description: standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: added to vedolizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: added to vedolizumab